
A New Dosing Strategy Improves Clozapine’s Tolerability
Harnessing this drug interaction can reduce clozapine's metabolic risks, but it needs to be done with care.
Harnessing this drug interaction can reduce clozapine's metabolic risks, but it needs to be done with care.
When a patient with schizophrenia does not respond to two antipsychotics, a trial of clozapine is in order. It is the only antipsychotic that can work when others have not, the only one that does not cause tardive dyskinesia, and one of few that improves negative symptoms. Only two things stand in its way, and they are big ones with clozapine: Safety and tolerability.
Two recent studies shift that risk-benefit ratio, and they are reviewed in this video. One is a
References
1. Lu ML, Chen TT, Kuo PH, et al.
2. Vermeulen JM, van Rooijen G1, van de Kerkhof MPJ, et al.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.